Eosinophilic Esophagitis in Adults: an Update on Medical Management
- 830 Downloads
Management of eosinophilic esophagitis (EoE) centers around the 3 Ds: diet, drug therapy, and dilation. Unfortunately, there is not a consistent relationship between symptom relief and resolution of mucosal eosinophilia. Elemental diets are very successful in children, but poorly tolerated by adults. The 6-food elimination diet is more attractive to adults, especially for those individuals with multiple food allergies. Steroids are the preferred anti-eosinophil drug for EoE. Oral prednisone is infrequently used because of side effects. Topical swallowed preparations (fluticasone, budesonide) are preferred for acute and possibly maintenance therapy. Relapses off steroids are frequent and dysphagia does not predictably improve. Esophageal dilation is key treatment for patients with the fibrostenotic phenotype of EoE. Long-term symptom relief for 1–2 years is common. Post-procedure chest pain is to be expected but perforation is very rare. A suggested algorithm for the treatment of EoE based on endoscopic phenotypes is outlined.
KeywordsEosinophilic esophagitis Allergy testing Elemental diet 6-food elimination diet Corticosteroids Prednisone Fluticasone Budesonide Proton pump inhibitors Esophageal dilation
Conflict of Interest
Ricardo Prieto declares that he has no conflict of interest.
Joel E. Richter declares that he has no conflict of interest.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 7.Abonia JP, Franciosi JP, Rothenberg ME. TGF-beta1: mediator of a feedback loop in eosinophilic esophagitis—or should we really say mastocytic esophagitis? J. Allergy Clin Immunol 126:1205–7Google Scholar
- 16.• Molina-Infante J, Ferrando-Lamana L, Ripoll C, Hernandez-Alonso M, Mateos JM, Fernandez-Bermejo M, et al. Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults. Clin Gastroenterol Hepatol. 2011;9:110–7. Study highlights the complex relationship of GERD and mucosal eosinophilia and helps identify the subset of PPI responsive EoE. PubMedCrossRefGoogle Scholar
- 18.Cheng E, Zhang X, Huo X, Yu C, Zhang Q, Wang DH, Spechler SJ, Souza RF. Omeprazole blocks eotaxin 3 expression by oesophageal squamous cells from patients with eosinophilic esophagitis and GORD. Gut 2012.Google Scholar
- 19.Hirano I. Therapeutic End Points in Eosinophilic Esophagitis: Is Elimination of Esophageal Eosinophils Enough? Clin Gastroenterol Hepatol 2012Google Scholar
- 24.Peterson K, Clayton F, Vinson LA, Fang JC, Boynton KK, Gleich GJ, et al. Utility of an elemental diet in adult with eosinophilic esophagitis. Gastroenterology. 2011;140.Google Scholar
- 25.Molina-Infante J et al. Efficacy of elimination diet based on food sensitization skin testing for adult eosinophilic esophagitis. Gastroenterology. 2012;142 suppl 2:abstract.Google Scholar
- 28.• Gonsalves N, Yang GY, Doerfler B, Ritz S, Ditto AM. Hirano I.Elimination diet effectively treats eosinophilic esophagitis in adults: food reintroduction identifies causative factors. Gastroenterology. 2012;142(7):1451–9. Reviews the impact of the 6-food elimination diet in adults with EoE. PubMedCrossRefGoogle Scholar
- 33.•• Alexander JA, Jung KW, Arora AS, Enders F, Katzka DA, Kephardt GM, Kita H, Kryzer LA, Romero Y, Smyrk TC, Talley NJ. Swallowed Fluticasone Improves Histologic but Not Symptomatic Responses of Adults with Eosinophilic Esophagitis. Clin Gastroenterol Hepatol 2012. Study highlights the inconsistent improvement of EoE symptoms in patients treated with topical steroids. Authors could not explain the dichotomy as eosinophilia was nearly eradicated. Google Scholar
- 35.• Straumann A, Conus S, Degen L, Frei C, Bussman C, Beglinger C, et al. Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2011;9:400–9. Maintenance budesonide keeps some patients with EoE in symptomatic remission for up to a year with evidence of resolving esophageal fibrosis. PubMedCrossRefGoogle Scholar
- 37.Spergel JM, Rothenberg ME, Collins MH, Futura GT, Markowitz JE, Fuchs 3rd G, et al. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2012;129(2):456–63. 463.e1-3.PubMedCrossRefGoogle Scholar
- 41.• Schoepfer AM, Gonsalves N, Bussmann C, et al. Esophageal dilation in eosinophilic esophagitis: effectiveness, safety, and impact on the underlying inflammation. Am J Gastroenterol. 2010;105:1062–70. Important study identifying the trade-offs of esophageal dilation in adults with EoE – “no pain, no gain”. PubMedCrossRefGoogle Scholar
- 43.Dellon E, Wood G, Rubinas T. Esophageal dilation in eosinophilic esophagitis: safety and predictors of clinical response and complications. Clin Endosc. 2010;71:706–12.Google Scholar